Use of strontium as a treatment method for osteoporosis

Current Osteoporosis Reports

Volumn 9, Issue 1, 2011, Pages 25-30

  Cortet, Bernard ^a  

^a Rheumatology Department   (France)

Author keywords

Antifracture efficacy; Hip fracture; Nonvertebral fracture; Osteoporosis; Strontium ranelate; Vertebral fracture

Indexed keywords

ALENDRONIC ACID; CALCIUM; ESTROGEN; GESTAGEN; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; VITAMIN D;

AMNESIA; ARTICLE; BACKACHE; BODY HEIGHT; BONE DEMINERALIZATION; BONE DENSITY; CHRONIC PAIN; CONSCIOUSNESS DISORDER; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; ECZEMA; FEMUR NECK FRACTURE; FRACTURE; FRAGILITY FRACTURE; HEADACHE; HIP FRACTURE; HUMAN; INJURY SEVERITY; LONG TERM CARE; NAUSEA; NEUROLOGIC DISEASE; OSTEOLYSIS; OSTEOPENIA; OUTCOME ASSESSMENT; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; RISK FACTOR; RISK REDUCTION; SEIZURE; SKIN ALLERGY; SPINE RADIOGRAPHY; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE; VITAMIN SUPPLEMENTATION; WOMEN'S HEALTH;

EID: 79551528026     PISSN: 15441873     EISSN: 15442241     Source Type: Journal    
DOI: 10.1007/s11914-010-0042-z     Document Type: Article

References (34)

1. J-Y Reginster N Burlet 2006 Osteoporosis: a still increasing prevalence Bone 38 Suppl. 1 S4 S9 10.1016/j.bone.2005.11.024 16455317 (Pubitemid 43190767)
2. C Cooper G Campion LJ Melton 3rd 1992 Hip fractures in the elderly: a world-wide projection Osteoporosis Int 2 285 9 1:STN:280:DyaK3s%2Fktlyrtw%3D%3D 10.1007/BF01623184
3. R Burge B Dawson-Hughes DH Solomon, et al. 2007 Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025 J Bone Miner Res 22 465 75 10.1359/jbmr.061113 17144789 (Pubitemid 46797130)
4. B Gullberg O Johnell JA Kanis 1997 Worldwide projections for hip fracture Osteoporos Int 7 407 13 1:STN:280:DyaK1c%2Fos1Kgtg%3D%3D 10.1007/PL00004148 9425497 (Pubitemid 27443065)
5. CL Leibson AN Tosteson SE Gabriel JE Ransom LJ Melton 2002 Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study J Am Geriatr Soc 50 1644 50 10.1046/j.1532-5415.2002. 50455.x 12366617 (Pubitemid 35192535)
6. E Canalis M Hott P Deloffre PJ Marie 1996 The divalent strontium S129 enhances bone cell replication and bone formation in vitro Bone 18 517 23 1:CAS:528:DyaK28Xkslagu7k%3D 10.1016/8756-3282(96)00080-4 8805991 (Pubitemid 26257871)
7. GJ Atkins KJ Weldon P Halbout DM Findlay 2009 Strontium ranelate treatment of primary osteoblasts promotes an osteocyte-like phenotype while eliciting and osteoprotegerin response Osteoporos Int 20 653 64 1:CAS:528:DC%2BD1MXis1Glurs%3D 10.1007/s00198-008-0728-6 18763010
8. P Amman V Shen B Robin, et al. 2004 Strontium ranelate improves bone resistance by increasing bone mass and improving architecture in intact female rats J Bone Miner Res 19 2012 2020 10.1359/jbmr.040906 (Pubitemid 41103416)
9. PJ Meunier C Roux E Seeman, et al. 2004 The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis N Engl J Med 350 459 68 1:CAS:528:DC%2BD2cXos1Snsw%3D%3D 10.1056/NEJMoa022436 14749454 (Pubitemid 38133766)
10. JY Reginster E Seeman MC De Vernejoul, et al. 2005 Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study J Clin Endocrinol Metab 90 2816 22 1:CAS:528:DC%2BD2MXkt1Wgt78%3D 10.1210/jc.2004-1774 15728210 (Pubitemid 40686329)
11. C Roux J Fechtenbaum S Kolta, et al. 2008 Strontium ranelate reduces the risk of vertebral fracture in young postmenopausal women with severe osteoporosis Ann Rheum Dis 67 1736 8 1:STN:280:DC%2BD1cjjsVersw%3D%3D 10.1136/ard.2008.094516 18713788 In this study, the authors demonstrated that SR is efficacious in terms of fracture reduction whatever the level of risk factors for fracture at baseline.
12. PJ Meunier C Roux S Ortolani, et al. 2009 Effect of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis Osteoporos Int 20 1663 73 1:CAS:528:DC%2BD1MXhtVygt7zI 10.1007/s00198-008-0825-6 19153678 In this study, the authors demonstrated that efficacy of SR for preventing vertebral facture is maintained for 4 years.
13. JY Reginster D Felsenberg S Boonen, et al. 2008 Effects of long-term strontium ranelate treatment on the risk of non-vertebral and vertebral fractures in postmenopausal osteoporosis: results of a 5-year, randomized, placebo-controlled trial Arthritis Rheum 58 1687 95 1:CAS:528: DC%2BD1cXotVOntrg%3D 10.1002/art.23461 18512789 In this study, the authors demonstrated that SR is efficacious for preventing nonvertebral and vertebral fracture for 5 years. (Pubitemid 351847521)
14. E Seeman S Boonen F Borgstrom, et al. 2010 Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life years in women over 80 years of age Bone 46 1038 42 1:CAS:528:DC%2BC3cXjs1aksLg%3D 10.1016/j.bone.2009.12.006 20026265 In this study, the authors demonstrated that SR is efficacious for preventing both vertebral and nonvertebral fractures for women over 80 years of age.
15. JY Reginster O Bruyere A Sawicki, et al. 2009 Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years Bone 45 1059 64 1:CAS:528:DC%2BD1MXhtlGit7bE 10.1016/j.bone.2009.08.004 19679207 In this study, the authors demonstrated that SR increase BMD both at the lumbar and the hip for a 8-year period with no plateau effect.
16. C Roux 2008 Strontium ranelate: short- and long-term benefits for post-menopausal women with osteoporosis Rheumatology 47 Suppl4 iv20 22 1:CAS:528:DC%2BD1cXns1Snt7Y%3D 10.1093/rheumatology/ken166 18556647 (Pubitemid 351865958)
17. Z Li AA Chines MP Meredith 2004 Statistical validation of surrogate endpoints: is bone density a valid surrogate for fracture? J Musculoskelet Neuronal Interact 4 64 74 1:CAS:528:DC%2BD2cXosF2qu74%3D 15615079
18. PD Delmas Z Li C Cooper 2004 Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses J Bone Miner Res 19 330 7 1:CAS:528:DC%2BD2cXhs1elsrg%3D 10.1359/JBMR.0301228 14969404 (Pubitemid 38116748)
19. O Bruyere C Roux J Detilleux, et al. 2007 Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate J Clin Endocrinol Metab 92 3076 81 1:CAS:528: DC%2BD2sXptl2hsb0%3D 10.1210/jc.2006-2758 17566094 (Pubitemid 47236373)
20. O Bruyere C Roux J Badurski, et al. 2007 Relationship between change in femoral neck bone mineral density and hip fracture incidence during treatment with strontium ranelate Curr Med Res Opin 12 3041 5 10.1185/030079907X242818
21. PD Delmas E Seeman 2004 Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with antiresorptive therapy Bone 34 599 604 1:CAS:528:DC%2BD2cXisF2ntL4%3D 10.1016/j.bone.2003.12. 022 15050889 (Pubitemid 38393794)
22. C Roux JY Reginster J Fechtenbaum, et al. 2006 Vertebral fracture risk reduction with strontium ranelate in women with postmenopausal osteoporosis is independent of baseline risk factors J Bone Miner Res 21 536 42 1:CAS:528:DC%2BD28Xkt1Kqsrc%3D 10.1359/jbmr.060101 16598373
23. ES Siris YT Chen TA Abbott, et al. 2004 Bone mineral density thresholds for pharmacological intervention to prevent fractures Arch Intern Med 164 1108 12 10.1001/archinte.164.10.1108 15159268 (Pubitemid 38668990)
24. KM Sanders GC Nicholson JJ Watts, et al. 2006 Half the burden of fragility fractures in the community occur in women without osteoporosis. When is fracture prevention cost effective? Bone 38 694 700 10.1016/j.bone.2005.06. 004 16507356
25. JA Kanis O Johnell DM Black, et al. 2008 Effects of raloxifene on the risk of new vertebral fracture in postmenopausal women with osteopenia or osteoporosis: a reanalysis of the multiple outcomes of raloxifene evaluation trial Bone 33 293 300 10.1016/S8756-3282(03)00200-X
26. SA Quandt DE Thompson DL Schneider MC Nevitt DM Black 2005 Fracture intervention trial research group. Effect of alendronate on vertebral fracture risk in women with bone numeral density T scores of -1, 6 to -2, 5 at the femoral neck: the fracture intervention trial Mayo Clin Proc 80 343 9 1:CAS:528:DC%2BD2MXis1SltL0%3D 10.4065/80.3.343 15757015
27. RP Heaney TM Zizic I Fogelman 2002 Risedronate reduces the risk of first vertebral fracture in osteoporotic women Oseoporosis Int 13 501 5 1:CAS:528:DC%2BD38Xmt1OhsL0%3D 10.1007/s001980200061 (Pubitemid 34742210)
28. E Seeman JP Devogelaer R Lorenc, et al. 2008 Strontium ranelate reduces the risk of vertebral fractures in patients with osteopaenia J Bone Miner Res 23 433 8 1:CAS:528:DC%2BD1cXjsl2itbo%3D 10.1359/jbmr.071105 17997711 In this study, the authors demonstrated that SR is efficacious for preventing vertebral fractures for women with osteopenia (and not osteoporosis) at baseline (Pubitemid 351304674)
29. JA Cauley J Robbins Z Chen, et al. 2003 Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial JAMA 290 1729 38 1:CAS:528:DC%2BD3sXnvVyiu70%3D 10.1001/jama.290.13.1729 14519707 (Pubitemid 37430623)
30. JA Kanis IP Barton O Johnell 2005 Risedronate decreases fracture risk in patients selected sofety on the basis of prior vertebral fracture Osteoporos Int 16 475 82 1:CAS:528:DC%2BD2MXlsFSku7Y%3D 10.1007/s00198-004-1698-y 15875093
31. MC Newitt B Ettinger DM Black, et al. 1998 The association of radiographically detected vertebral fractures with back pain and function: a prospective study Ann Intern Med 128 793 800
32. S Boonen 2006 Addressing and meeting the needs of osteoporotic patients with strontium ranelate: a review Curr Opin Rheumatol 18 Suppl 1 S21 S27 10.1097/01.bor.0000229524.97170.83 16735842 (Pubitemid 44289186)
33. G Breart C Cooper O Meyer, et al. 2009 Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database Osteoporos Int 20 1 7 In this study, the authors demonstrated by using the UK General Practice Research Database that thromboembolism risk is not increased for patients treated by SR compared with patients treated by alendronate or osteoporotic patients not receiving treatment for osteoporosis.
34. JA Kanis N Burlet C Cooper, et al. 2008 European Society for clinical and economic aspects of osteoporosis and osteoarthritis (ESCEO) European guidance for the diagnosis and management of osteoporosis in postmenopausal women Osteoporosis Int 19 399 428 1:STN:280:DC%2BD1c3itFekuw%3D%3D 10.1007/s00198-008-0560-z On this position paper on behalf of the ESCEO, the authors indicate that SR is efficacious for preventing both vertebral and nonvertebral fractures for women with osteoporosis but also established osteoporosis.